News

The '18th China Listed Company Value Forum and 2024 New Quality Productivity Tour in Yangtze River Delta', organised by the Securities Times, was recently held in Kunshan. At the forum, the '18th China Listed Company Value Award' list was revealed, with Autobio being named one of the 'Top 100 Chinese Listed Companies in terms of Mainboard Value'.

The 'China Listed Company Value Award', sponsored by the Securities Times, is a selection activity designed to identify the value of listed companies in China's capital market. It has become one of the most influential selections in the field of listed companies organised by domestic mainstream financial media. This year's awards take a comprehensive approach to assessing the performance of listed companies in a number of key areas, including operation, finance, innovation, market influence and social responsibility. Following a period of intense competition spanning over two months, the 18th China Listed Company Value Award was formally announced at the forum.

Over the years, Autobio has continued to introduce high-quality products and services for the healthcare sector, driven by technological innovation, and has achieved consistent growth in its operating results. In the future, Autobio will continue to pursue high-quality growth through innovation, with the goal of becoming a leading in-vitro diagnostic enterprise that seamlessly integrates advanced manufacturing and high-end services.

The selection of Autobio as one of the 'Top 100 Chinese Listed Companies in terms of Mainboard Value' is a testament to Autobio's exemplary performance in corporate governance, business performance, innovation and social responsibility over the years. Autobio will continue to spearhead the advancement of China's healthcare industry.